Premium
FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS
Author(s) -
Ishitsuka K,
Izutsu K,
Maruyama D,
Makita S,
Jacobsen E. D,
Horwitz S,
Kusumoto S,
Allen P,
Porcu P,
Imaizumi Y,
Yamauchi N,
Morishima S,
Kawamata T.,
Foss F. M,
Utsunomiya A,
Nosaka K,
Serbest G,
Kato K,
Adachi N,
Tsukasaki K,
Tobinai K
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.14_2879
Subject(s) - ezh2 , refractory (planetary science) , cancer research , dual (grammatical number) , enhancer , lysine , medicine , histone , chemistry , biology , gene , biochemistry , gene expression , art , literature , amino acid , astrobiology
Enhancer of zeste homolog 2 (EZH2) and its close homolog, EZH1, catalyze the attachment of 3 methyl groups to histone H3 at lysine 27. Altered EZH2 expression is implicated in the etiology of non‐Hodgkin lymphomas (NHLs). Valemetostat tosylate (DS‐3201b; valemetostat) is a novel, potent, and selective dual inhibitor of EZH2 and EZH1. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.